Douglas Hunt
General Counsel bei PUMA BIOTECHNOLOGY, INC.
Vermögen: 386 745 $ am 30.04.2024
Profil
Douglas Hunt is currently the Senior VP-Law, Regulatory & Medical Affairs at Puma Biotechnology, Inc. He previously worked as the Executive Director-Therapeutic Area at Amgen, Inc. from 2000 to 2008.
From 2008 to 2015, he was the Vice President-Global Regulatory Affairs at Baxter Healthcare Corp.
He then served as the VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. from 2015 to 2017.
Mr. Hunt obtained his undergraduate degree from the University of Portsmouth.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0,16% | 22.04.2024 | 79 251 ( 0,16% ) | 386 745 $ | 30.04.2024 |
Aktive Positionen von Douglas Hunt
| Unternehmen | Position | Beginn |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | General Counsel | 01.01.2018 |
Ehemalige bekannte Positionen von Douglas Hunt
| Unternehmen | Position | Ende |
|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | General Counsel | 01.12.2017 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | General Counsel | 01.01.2015 |
| AMGEN INC. | Corporate Officer/Principal | 01.07.2008 |
Ausbildung von Douglas Hunt
| University of Portsmouth | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
